Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. KEGG DRUG DrugBank 薬物名（臨床試験情報から抽出） KEGG GENES KEGG PATHWAY 指定難病告示番号
1 Etoposide 1件: Etoposide1件: Etoposide; 2件: TOP2A,
TOP2B 💬		1件: Platinum drug resistance 💬11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
2 Cyclosporine 1件: Cyclosporine10件: Ciclosporin; CICLOSPORINA; Ciclosporine; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine A; Ikervis; Neoral; Restasis; 5件: PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		33件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬44件: 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
3 Cyclophosphamide 1件: Cyclophosphamide6件: Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamidum; Cytoxan; --44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331
4 Lamivudine 1件: Lamivudine4件: COMBIVIR; Epivir; Lamivudine; Triumeq; --8件: 2, 26, 42, 46, 135, 256, 265, 325
5 Valproic acid 1件: Valproic acid3件: Valproate; VALPROATE SODIUM; Valproic Acid; 7件: ABAT,
ALDH5A1,
CACNA1G,
CACNA1H,
CACNA1I,
GAD1,
GAD2 💬		17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬14件: 2, 3, 5, 6, 13, 26, 65, 85, 90, 102, 127, 222, 233, 256
6 Methylprednisolone 1件: Methylprednisolone4件: Medrol; Methylprednisolon; Methylprednisolone; METHYLPREDNISOLONE ACETATE; 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬46件: 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296
7 Zidovudine 1件: Zidovudine3件: COMBIVIR; Retrovir; Zidovudine; --7件: 25, 26, 94, 135, 265, 325, 331
8 Prednisolone 1件: Prednisolone3件: Prednisolona; Prednisolone; Prednisolonum; 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬42件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300
9 Prednisone 1件: Prednisone3件: Prednisona; Prednisone; RAYOS; 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬45件: 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331
10 Pentoxifylline 1件: Pentoxifylline1件: Pentoxifylline; --12件: 26, 56, 84, 86, 93, 96, 97, 113, 220, 222, 296, 298
11 Tamibarotene 1件: Tamibarotene1件: Tamibarotene; 1件: RARA 💬5件: Acute myeloid leukemia, Estrogen signaling pathway, Pathways in cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬2件: 26, 96
12 Rituximab 1件: Rituximab6件: MabThera; Rituxan; Rituximab; Rixathon; Ruxience; TRUXIMA; 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
13 Bortezomib 1件: Bortezomib3件: BORTEZOMIB; Bortezomib Accord; VELCADE; 1件: PSMB5 💬8件: Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬17件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 222, 228, 256, 283, 288, 331
14 Filgrastim 1件: Filgrastim7件: Filgrastim; Filgrastim Hexal; G-CSF; Granulocyte Colony Stimulating Factor; NEUPOGEN; TEVAGRASTIM; Zarzio; 1件: CSF3R 💬5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬35件: 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
15 Interferon alfa 1件: Interferon alfa1件: Interferon alfa; 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬6件: 13, 25, 26, 28, 56, 96
16 Doxorubicin 1件: Doxorubicin2件: Doxorubicin; Doxorubicin Hydrochloride; 2件: TOP2A,
TOP2B 💬		1件: Platinum drug resistance 💬5件: 26, 28, 34, 65, 331
17 Interferon beta-1a 1件: Interferon beta-1a6件: AVONEX; Interferon Beta 1-A; Interferon Beta 1a; Interferon beta-1a; Interferon-beta-1a; REBIF; 2件: IFNAR1,
IFNAR2 💬		18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬4件: 13, 26, 96, 97
18 Lenalidomide 1件: Lenalidomide2件: Lenalidomide; REVLIMID; 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬8件: 16, 26, 28, 34, 49, 284, 300, 331
19 Raltegravir 1件: Raltegravir2件: ISENTRESS; Raltegravir; --4件: 13, 26, 93, 265
20 Cyclophosphamide 1件: Cyclophosphamide6件: Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; CYCLOPHOSPHAMIDE; Cyclophosphamidum; Cytoxan; --44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331
21 Vincristine 1件: Vincristine2件: Vincristine; Vincristine Sulfate; 9件: TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬		10件: Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬4件: 26, 34, 65, 331
22 Mogamulizumab 1件: Mogamulizumab1件: Mogamulizumab; 1件: CCR4 💬5件: Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Kaposi sarcoma-associated herpesvirus infection, Viral carcinogenesis, Viral protein interaction with cytokine and cytokine receptor 💬1件: 26
23 Teriflunomide 1件: Teriflunomide2件: AUBAGIO; TERIFLUNOMIDE; 1件: DHODH 💬3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬3件: 13, 25, 26
24 Nivolumab 1件: Nivolumab1件: Nivolumab; 1件: PDCD1 💬3件: Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway 💬12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159